{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:31:09Z","timestamp":1792812669645,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T00:00:00Z","timestamp":1650672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T00:00:00Z","timestamp":1650672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s12325-022-02117-1","type":"journal-article","created":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T08:02:51Z","timestamp":1650700971000},"page":"2906-2919","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Disease Progression Stages and Burden in Patients with Duchenne Muscular Dystrophy Using Administrative Claims Supplemented by Electronic Medical Records"],"prefix":"10.1007","volume":"39","author":[{"given":"Joel","family":"Iff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6246-2292","authenticated-orcid":false,"given":"Yi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepshekhar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xander","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Henricson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"CINRG DNHS Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,23]]},"reference":[{"issue":"1","key":"2117_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7(1):13.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2117_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/ijns3020008","volume":"3","author":"SA Al-Zaidy","year":"2017","unstructured":"Al-Zaidy SA, Lloyd-Puryear M, Kennedy A, Lopez V, Mendell JR. A roadmap to newborn screening for Duchenne muscular dystrophy. Int J Neonatal Screen. 2017;3(2):8.","journal-title":"Int J Neonatal Screen"},{"issue":"6","key":"2117_CR3","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/mus.26441","volume":"59","author":"AM Connolly","year":"2019","unstructured":"Connolly AM, Zaidman CM, Golumbek PT, et al. Twice-weekly glucocorticosteroids in infants and young boys with Duchenne muscular dystrophy. Muscle Nerve. 2019;59(6):650\u20137.","journal-title":"Muscle Nerve"},{"issue":"2","key":"2117_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3233\/PRM-2009-0071","volume":"2","author":"V Spehrs-Ciaffi","year":"2009","unstructured":"Spehrs-Ciaffi V, Fitting JW, Cotting J, Jeannet PY. Respiratory surveillance of patients with Duchenne and Becker muscular dystrophy. J Pediatr Rehabil Med. 2009;2(2):115\u201322.","journal-title":"J Pediatr Rehabil Med"},{"issue":"6","key":"2117_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1212\/WNL.0000000000000669","volume":"83","author":"E Landfeldt","year":"2014","unstructured":"Landfeldt E, Lindgren P, Bell CF, et al. The burden of Duchenne muscular dystrophy: an international, cross-sectional study. Neurology. 2014;83(6):529\u201336.","journal-title":"Neurology"},{"key":"2117_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13023-014-0210-9","volume":"9","author":"O Schreiber-Katz","year":"2014","unstructured":"Schreiber-Katz O, Klug C, Thiele S, et al. Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies in Germany. Orphanet J Rare Dis. 2014;9:210.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"2117_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1212\/WNL.0000000000002337","volume":"86","author":"D Gloss","year":"2016","unstructured":"Gloss D, Moxley RT 3rd, Ashwal S, Oskoui M. Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2016;86(5):465\u201372.","journal-title":"Neurology"},{"key":"2117_CR8","unstructured":"PTC Therapeutics. 2014 PTC Therapeutics receives conditional approval in the European Union for Translarna\u2122 for the treatment of nonsense mutation Duchenne muscular dystrophy. http:\/\/ir.ptcbio.com\/releasedetail.cfm?releaseid=863914. Accessed 6 Mar 2022."},{"key":"2117_CR9","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation. Accessed 6 Mar 2022."},{"issue":"Suppl 2","key":"2117_CR10","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1542\/peds.2018-0333H","volume":"142","author":"DW Sheehan","year":"2018","unstructured":"Sheehan DW, Birnkrant DJ, Benditt JO, et al. Respiratory management of the patient with Duchenne muscular dystrophy. Pediatrics. 2018;142(Suppl 2):S62\u201371.","journal-title":"Pediatrics"},{"issue":"Suppl 2","key":"2117_CR11","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1542\/peds.2018-0333D","volume":"142","author":"LE Case","year":"2018","unstructured":"Case LE, Apkon SD, Eagle M, et al. Rehabilitation management of the patient with Duchenne muscular dystrophy. Pediatrics. 2018;142(Suppl 2):S17\u201333.","journal-title":"Pediatrics"},{"issue":"4","key":"2117_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3233\/JND-170280","volume":"4","author":"Z Koeks","year":"2017","unstructured":"Koeks Z, Bladen CL, Salgado D, et al. Clinical outcomes in Duchenne muscular dystrophy: a study of 5345 patients from the TREAT-NMD DMD global database. J Neuromuscul Dis. 2017;4(4):293\u2013306.","journal-title":"J Neuromuscul Dis"},{"key":"2117_CR13","doi-asserted-by":"publisher","first-page":"32045","DOI":"10.3402\/qhw.v11.32045","volume":"11","author":"H Fujino","year":"2016","unstructured":"Fujino H, Iwata Y, Saito T, Matsumura T, Fujimura H, Imura O. The experiences of patients with Duchenne muscular dystrophy in facing and learning about their clinical conditions. Int J Qual Stud Health Well-being. 2016;11:32045.","journal-title":"Int J Qual Stud Health Well-being"},{"key":"2117_CR14","doi-asserted-by":"crossref","unstructured":"Muntoni F, Domingos J, Manzur AY, et al. Categorising trajectories and individual item changes of the North Star ambulatory assessment in patients with Duchenne muscular dystrophy. PLoS One. 2019;14(9):e0221097.","DOI":"10.1371\/journal.pone.0221097"},{"key":"2117_CR15","doi-asserted-by":"crossref","unstructured":"Goemans N, Wong B, Van den Hauwe M, et al. Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: a multi-institutional collaboration. PLoS One. 2020;15(6):e0232870.","DOI":"10.1371\/journal.pone.0232870"},{"issue":"10","key":"2117_CR16","doi-asserted-by":"publisher","first-page":"e1381","DOI":"10.1212\/WNL.0000000000010170","volume":"95","author":"N Goemans","year":"2020","unstructured":"Goemans N, Signorovitch J, Sajeev G, et al. Suitability of external controls for drug evaluation in Duchenne muscular dystrophy. Neurology. 2020;95(10):e1381\u201391.","journal-title":"Neurology"},{"issue":"3","key":"2117_CR17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2217\/cer-2019-0170","volume":"9","author":"JR Marden","year":"2020","unstructured":"Marden JR, Freimark J, Yao Z, Signorovitch J, Tian C, Wong BL. Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center. J Comp Eff Res. 2020;9(3):177\u201389.","journal-title":"J Comp Eff Res"},{"issue":"9","key":"2117_CR18","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1002\/1097-4598(200009)23:9<1344::AID-MUS4>3.0.CO;2-F","volume":"23","author":"MD Bonifati","year":"2000","unstructured":"Bonifati MD, Ruzza G, Bonometto P, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve. 2000;23(9):1344\u20137.","journal-title":"Muscle Nerve"},{"issue":"20","key":"2117_CR19","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1212\/WNL.0000000000003217","volume":"87","author":"RC Griggs","year":"2016","unstructured":"Griggs RC, Miller JP, Greenberg CR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016;87(20):2123\u201331.","journal-title":"Neurology"},{"issue":"12","key":"2117_CR20","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1212\/WNL.0000000000001950","volume":"85","author":"L Bello","year":"2015","unstructured":"Bello L, Gordish-Dressman H, Morgenroth LP, et al. Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne natural history study. Neurology. 2015;85(12):1048\u201355.","journal-title":"Neurology"},{"issue":"10119","key":"2117_CR21","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","volume":"391","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391(10119):451\u201361.","journal-title":"Lancet"},{"issue":"1","key":"2117_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/mus.23807","volume":"48","author":"CM McDonald","year":"2013","unstructured":"McDonald CM, Henricson EK, Abresch RT, et al. The Cooperative International Neuromuscular Research Group Duchenne natural history study\u2013a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve. 2013;48(1):32\u201354.","journal-title":"Muscle Nerve"},{"key":"2117_CR23","unstructured":"Centers for Medicare & Medicaid Services. 2021 ICD-10-CM. https:\/\/www.cms.gov\/medicare\/icd-10\/2021-icd-10-cm. Accessed 6 Mar 2022."},{"issue":"2","key":"2117_CR24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40273-016-0461-5","volume":"35","author":"E Landfeldt","year":"2017","unstructured":"Landfeldt E, Alfredsson L, Straub V, Lochmuller H, Bushby K, Lindgren P. Economic evaluation in Duchenne muscular dystrophy: model frameworks for cost-effectiveness analysis. Pharmacoeconomics. 2017;35(2):249\u201358.","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"2117_CR25","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/acr.20184","volume":"62","author":"KP Liao","year":"2010","unstructured":"Liao KP, Cai T, Gainer V, et al. Electronic medical records for discovery research in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2010;62(8):1120\u20137.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2117_CR26","doi-asserted-by":"crossref","unstructured":"Mirelman A, Ben Or Frank M, Melamed M, et al. Detecting sensitive mobility features for Parkinson's disease stages via machine learning. Mov Disord. 2021;36(9):2144\u201355.","DOI":"10.1002\/mds.28631"},{"issue":"8","key":"2117_CR27","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.jclinepi.2014.02.019","volume":"67","author":"EI Benchimol","year":"2014","unstructured":"Benchimol EI, Guttmann A, Mack DR, et al. Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario. Canada J Clin Epidemiol. 2014;67(8):887\u201396.","journal-title":"Canada J Clin Epidemiol"},{"issue":"6","key":"2117_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1177\/106286069901400607","volume":"14","author":"PL Hebert","year":"1999","unstructured":"Hebert PL, Geiss LS, Tierney EF, Engelgau MM, Yawn BP, McBean AM. Identifying persons with diabetes using Medicare claims data. Am J Med Qual. 1999;14(6):270\u20137.","journal-title":"Am J Med Qual"},{"issue":"6","key":"2117_CR29","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/mus.24965","volume":"53","author":"LJ Teoh","year":"2016","unstructured":"Teoh LJ, Geelhoed EA, Bayley K, Leonard H, Laing NG. Health care utilization and costs for children and adults with Duchenne muscular dystrophy. Muscle Nerve. 2016;53(6):877\u201384.","journal-title":"Muscle Nerve"},{"issue":"6","key":"2117_CR30","first-page":"633","volume":"23","author":"S Thayer","year":"2017","unstructured":"Thayer S, Bell C, McDonald CM. The direct cost of managing a rare disease: assessing medical and pharmacy costs associated with Duchenne muscular dystrophy in the United States. J Manag Care Spec Pharm. 2017;23(6):633\u201341.","journal-title":"J Manag Care Spec Pharm"},{"key":"2117_CR31","doi-asserted-by":"crossref","unstructured":"Stott-Miller M, Vlahiotis A, Palmer L. Treatment patterns, resource utilization and costs in muscular dystrophy patients: analysis using administrative claims data (Abstract). Value Health. 2015;18(7):PA764-A5.","DOI":"10.1016\/j.jval.2015.09.2507"},{"issue":"1","key":"2117_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","volume":"12","author":"S Ryder","year":"2017","unstructured":"Ryder S, Leadley RM, Armstrong N, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12(1):79.","journal-title":"Orphanet J Rare Dis"},{"issue":"S2","key":"2117_CR33","first-page":"S39","volume":"28","author":"O Mayer","year":"2018","unstructured":"Mayer O, Karafilidis J, Higgins K, Griffin B. Descriptive characteristics of males with Duchenne muscular dystrophy using insurance claims data. Neuromuscul Disord. 2018;28(S2):S39.","journal-title":"Neuromuscul Disord"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02117-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02117-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02117-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T10:38:32Z","timestamp":1653043112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02117-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,23]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["2117"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02117-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,23]]},"assertion":[{"value":"24 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}